Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:27:11.503Z.
Consensus retrieved: 2026-10-06T12:12:36.966Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:27:11.503Z.
Quote observation: 2026-10-06T15:24:47.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0d034b685c23fadaea9476ccc197406393d04780d3c67e2351ab6b6412cf62fb
Forward PE Ratio (N/A) = Dated Quote Price ($4.48) / Consensus Forward EPS ($-0.34)
FORWARD PE RATIO
N/A
Fractyl Health, Inc.
Market Cap
$59.23M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Fractyl Health, Inc. (GUTS) | $59.23M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.99M | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $60.15M | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $60.20M | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.21M | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.98M | N/A |
| Adicet Bio, Inc. (ACET)vs › | $60.92M | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.98M | N/A |
| InterCure Ltd. (INCR)vs › | $63.14M | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $63.23M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $4.48, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.34 | $-0.38 – $-0.31 | 4 | n/m |
| 2027-12-31 | $-0.39 | $-0.49 – $-0.32 | 4 | n/m |
| 2028-12-31 | $-0.25 | $-0.33 – $-0.16 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
